v3.24.0.1
Collaboration Agreements - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended 71 Months Ended
Jan. 27, 2023
USD ($)
Dec. 13, 2022
USD ($)
shares
Oct. 15, 2021
USD ($)
Apr. 02, 2018
Apr. 30, 2018
USD ($)
Target
$ / shares
shares
Feb. 28, 2018
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Shares issued under equity agreement | shares   10,683,761                
Investment, Type [Extensible Enumeration]   G S K Equity Investment [Member]                
Equity investment aggregate purchase price               $ 93,574,000 $ 51,220,000  
Purchase price per share | $ / shares                 $ 4.68  
Proceeds from issuance of ordinary shares               93,574,000 $ 51,220,000  
Revenue               113,305,000 3,649,000  
Collaboration revenue recognized               113,305,000 3,649,000  
Collaboration and license agreement, deferred revenue current               150,059,000 31,558,000 $ 150,059,000
Collaboration and license agreement, deferred revenue noncurrent               15,601,000 79,774,000 15,601,000
Takeda [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Fund receivable for research and preclinical activities         $ 60,000,000          
Up-front consideration received         $ 110,000,000          
Collaboration And License Agreement [Member] | Category One Programs [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Percentage of global costs and potential profits sharing ratio         50.00%          
Collaboration And License Agreement [Member] | Takeda [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment under collaboration agreement         $ 110,000,000          
Collaboration and license agreement month and year           2018-02        
Fund receivable for research and preclinical activities         $ 60,000,000          
Research term under collaboration and license agreement         4 years          
Collaboration agreement commencement date       Apr. 02, 2018            
Collaboration agreement termination period       180 days            
Collaboration And License Agreement [Member] | Takeda [Member] | Minimum [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Collaboration agreement, committed cash           $ 230,000,000        
Collaboration And License Agreement [Member] | Takeda [Member] | Category One Programs [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Percentage of global costs and potential profits sharing ratio         50.00%          
Collaboration and License Agreement Date     Oct. 15, 2021              
Revenue               47,000,000 3,300,000 128,200,000
Collaboration revenue recognized               47,000,000 3,300,000 128,200,000
Collaboration and license agreement, deferred revenue               71,300,000 111,300,000 71,300,000
Collaboration and license agreement, deferred revenue current               71,300,000 31,600,000 71,300,000
Collaboration and license agreement, deferred revenue noncurrent               $ 0 $ 79,800,000 0
Collaboration And License Agreement [Member] | Takeda [Member] | Category Two Programs [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Fund receivable for research and preclinical activities         $ 60,000,000          
Research term under collaboration and license agreement         4 years          
Maximum targets for preclinical programs | Target         6          
Option to reach maximum targets for preclinical programs               any one time    
Collaboration And License Agreement [Member] | Takeda [Member] | Category 1 Programs and Category 2 Programs [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Collaboration-budgeted research and preclinical expenses     $ 22,500,000              
Revenue     18,500,000              
Collaboration revenue recognized     $ 18,500,000              
C9-ALS/FTD Program [Member] | Takeda [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue from termination of collaborative arrangement             $ 28,000,000      
Collaborative Arrangement Transaction Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag             true      
GSK Collaboration Agreement [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment under collaboration agreement $ 120,000,000 $ 120,000,000                
Collaboration agreement in premium   $ 15,400,000                
Revenue recognized               $ 8,300,000    
Acheivement of milestone included in current portion receivable               20,000,000   20,000,000
Milestone payment               20,000,000    
Revenue               66,300,000    
Collaboration revenue recognized               66,300,000    
Collaboration and license agreement, deferred revenue               94,300,000   94,300,000
Collaboration and license agreement, deferred revenue current               78,700,000   78,700,000
Collaboration and license agreement, deferred revenue noncurrent               15,600,000   $ 15,600,000
Developmental Milestone related to HD Category One Program, Which Pertained to Completion of New, Non-Clinical Study of WVE-003 in Non-Human Primates or NHPs [Member] | Takeda [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue from termination of collaborative arrangement             $ 7,000,000      
SCA3 Category 1 Program [Member] | Takeda [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue from termination of collaborative arrangement               $ 9,900,000    
Collaborative Arrangement Transaction Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag               true    
Collaboration and Share Purchase Agreements [Member] | Takeda [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Shares issued under equity agreement | shares         1,096,892          
Purchase price per share | $ / shares         $ 54.7          
Proceeds from issuance of ordinary shares         $ 60,000,000          
Equity investment agreement official closure month and year         2018-04